Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC 268 vs Clindamycin for Acne Vulgaris
NCT03717506Phase 3Completed
- Sponsor
- Balmoral Medical
- Start
- Oct 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GDC-268 in acne vulgaris (3 arms), sponsored by Balmoral Medical. Primary endpoints: Mean Percent Change in the Number of Inflamed Lesions at 12 weeks and Mean Percent Change in the Non-inflammatory Lesion Counts at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
GDC-268
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03717506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717506.